Biomarker analysis of WJOG6410L/IMPACT: A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (Stage II-III) non-small cell lung cancer patients with EGFR mutation - WJOG6410LTR

Multivariate analysis showed that NOTCH1 co-mutation was a significant poor prognostic factor for OS in the gefitinib group and CREBBP co-mutation for DFS and OS in the cis/vin group. In patients with NOTCH1 co-mutations, OS was shorter in the gefitinib group, with a significant interaction (P for interaction=0.039). In patients with CREBBP co-mutations, DFS was longer in the gefitinib group, with a significant interaction (P for interaction=0.058).